Plasminogen activator inhibitor-1 impairs plasminogen activation-mediated vascular smooth muscle cell apoptosis

Patrick Rossignol1, Eduardo Anglès-Cano, Henri Roger Lijnen

  • 1Center for Molecular and Vascular Biology, K.U.Leuven, Leuven, Belgium.

Insights

Plasminogen activator inhibitor-1 (PAI-1) impairs plasmin-mediated apoptosis in vascular smooth muscle cells (VSMCs). Reducing PAI-1 accelerates VSMC apoptosis via plasminogen activation by tissue-type (t-PA) or urokinase-type (u-PA) plasminogen activators.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Cardiovascular Research

Background:

  • Vascular smooth muscle cell (VSMC) apoptosis plays a critical role in cardiovascular diseases.
  • Plasminogen activation system components, including plasminogen activator inhibitor-1 (PAI-1), are implicated in VSMC biology.
  • The precise role of PAI-1 in VSMC apoptosis mediated by plasminogen activation remains to be fully elucidated.

Purpose of the Study:

  • To investigate the role of plasminogen activator inhibitor-1 (PAI-1) in vascular smooth muscle cell (VSMC) apoptosis.
  • To determine how PAI-1 influences plasminogen activation and subsequent apoptotic processes in VSMCs.
  • To compare apoptosis rates in VSMCs with and without PAI-1, and with deficiencies in tissue-type (t-PA) or urokinase-type (u-PA) plasminogen activators.

Main Methods:

  • Utilized aortic VSMCs from PAI-1 deficient (PAI-1 (-/-)), t-PA deficient (t-PA (-/-)), u-PA deficient (u-PA (-/-)), and wildtype (WT) mice.
  • Assessed plasminogen activation rates on VSMC surfaces.
  • Quantified VSMC apoptosis using morphological analysis and apoptotic index measurements after incubation with plasminogen.

Main Results:

  • Plasminogen activation on VSMCs was concentration-dependent and saturable, with higher rates observed in PAI-1 (-/-) cells compared to WT, t-PA (-/-), or u-PA (-/-) cells.
  • Plasminogen activation was dependent on cell surface COOH-terminal lysine residues and plasminogen activator activity.
  • PAI-1 (-/-) VSMCs exhibited significantly earlier and higher rates of apoptosis when incubated with plasminogen, correlating with plasmin release.

Conclusions:

  • Plasmin-mediated apoptosis of VSMCs occurs through plasminogen activation by either t-PA or u-PA.
  • Plasminogen activator inhibitor-1 (PAI-1) significantly impairs plasmin-mediated VSMC apoptosis.
  • These findings highlight PAI-1 as a key regulator of VSMC apoptosis in the context of plasminogen activation.

Related Concept Videos

Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Vascular Spasm01:16

Vascular Spasm

The vascular phase, also known as vasospasm, is the initial stage of hemostasis, crucial for preventing excessive bleeding when a blood vessel is injured. After a vessel is cut, nerves in the damaged area trigger pain and other sensory impulses. Simultaneously, the smooth muscles in the vessel wall contract, resulting in a vascular spasm. This contraction reduces the vessel's diameter at the injury site, slowing or stopping blood loss through the vessel wall. Vascular spasms typically last for...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...